HOUSTON, Jan. 14, 2008 (PRIME NEWSWIRE) -- Encysive Pharmaceuticals Inc. (Nasdaq:ENCY) today announced the commercial availability of Thelin(r)(1) (sitaxentan sodium(2)) 100 mg tablets in Belgium and Luxembourg for the treatment of pulmonary arterial hypertension (PAH). Encysive received European Union (EU) marketing authorization for THELIN from the European Commission in August 2006. THELIN is the first selective endothelin A receptor antagonist, and the first once-daily oral treatment commercially available for PAH patients in the EU.
THELIN is indicated for improving exercise capacity in PAH patients classified as World Health Organization (WHO) functional class III. Efficacy has been shown in primary pulmonary hypertension(3) and pulmonary hypertension associated with connective tissue disease (CTD).
The European Commission's centralized licensing procedure permits Encysive to market THELIN in all 27 member states of the EU. THELIN has already been launched in the United Kingdom, Germany, Ireland, Spain, France, Italy and the Netherlands and will be launched in additional EU member states as local governmental approval for reimbursement is obtained.
"With the availability of THELIN to physicians and patients in Belgium and Luxembourg, our European commercialization strategy continues to move forward," said Thierry Plouvier, M.D., Vice President, Europe Operations, for Encysive (UK) Ltd. "THELIN adds an additional therapeutic option for treating patients with pulmonary arterial hypertension in the EU."
No comments:
Post a Comment